Abstract
The treatment result of 271 cases of advanced stage intermediate grade lymphoma were reviewed. Ninety-four patients received CHOP chemotherapy, 45 BACOP and 17 m-BACOD. The clinical characteristics of the three groups of patients were comparable. Patients receiving CHOP had a complete response (CR) rate of 60 per cent, the disease-free survival of CR patients was 31 per cent at 5 years. The overall survival following CHOP chemotherapy was 38 per cent at 5 years. The use of the BACOP or m-BACOD regime did not appear to improve significantly the prognosis of these patients. Clinical staging, B symptoms, age and serum lactate dehydrogenase level were the most important independent prognostic factors.
MeSH terms
-
Analysis of Variance
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Follow-Up Studies
-
Humans
-
L-Lactate Dehydrogenase / blood
-
Leucovorin / administration & dosage
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / pathology
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Neoplasm Staging
-
Prednisolone / administration & dosage
-
Prednisone / administration & dosage
-
Prognosis
-
Vincristine / administration & dosage
Substances
-
Bleomycin
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisolone
-
L-Lactate Dehydrogenase
-
Leucovorin
-
Prednisone
-
Methotrexate
Supplementary concepts
-
CHOP protocol
-
CHOP-B protocol
-
M-BACOP protocol